Related Experiment Videos
Effect of botulinum toxin type A on cerebral palsy with upper limb spasticity
Tsui Fen Yang1, Chung Pei Fu, Nien Tzu Kao
1Department of Physical Therapy, School of Medicine, National Yang-Ming University, Taipei, Taiwan.
Insights
Botulinum toxin type A injections effectively reduced upper limb spasticity and improved fine motor skills in children with cerebral palsy. This treatment also enhanced self-care capabilities and reduced caregiver burden.
Area of Science:
- Neurology
- Pediatric Rehabilitation
- Movement Disorders
Background:
- Cerebral palsy (CP) is a common neurodevelopmental disorder characterized by motor impairments, including spasticity.
- Upper limb spasticity in children with CP significantly impacts motor function and daily activities.
- Botulinum toxin type A (BoNT-A) is a neurotoxin used to treat focal muscle spasticity.
Purpose of the Study:
- To evaluate the efficacy of botulinum toxin type A injections in reducing upper limb spasticity in children with cerebral palsy.
- To assess the impact of BoNT-A on motor function, including fine motor skills and self-care capabilities.
- To investigate potential improvements in quality of life and caregiver burden.
Main Methods:
- A study involving 15 children with spastic cerebral palsy undergoing physical and occupational therapy.
- Administration of botulinum toxin type A injections to target muscle groups after 3 months of therapy.
- Outcome measurements included the Modified Ashworth Scale, Physician's Rating Scale, Bruininks-Oseretsky Test of Motor Proficiency, and Pediatric Evaluation of Disability Inventory at 6 and 12 weeks post-injection.
Main Results:
- Significant reduction in upper limb spasticity was observed post-BoNT-A injection compared to the control period.
- Improvements in upper limb Physician's Rating Scale scores and fine motor skills (Bruininks-Oseretsky Test) were significant.
- Enhanced self-care capabilities were noted at 12 weeks post-treatment; grasp and pinch strength showed no significant change.
Conclusions:
- Botulinum toxin type A injections are effective for reducing upper limb spasticity in children with cerebral palsy.
- BoNT-A treatment improves movement patterns and fine motor function, contributing to enhanced daily living activities.
- The study suggests a potential reduction in caregiver burden and an improvement in the quality of life for patients and their families.
Objective:
The objective of this study was to investigate the effects of botulinum toxin type A injections in reducing upper limb muscular spasticity and in improving motor function in children with cerebral palsy.
Design:
Fifteen children with spastic cerebral palsy who were undergoing regular physical and occupational therapy were enrolled. Botulinum toxin type A injections in clinically indicated target muscle groups were administered after the children had received 3 mo of therapy. A follow-up study was carried out at 6 wk and 12 wk, respectively, after the botulinum toxin type A injections. The main outcome measurements included the Modified Ashworth Scale, the upper limb Physician's Rating Scale, the Bruininks-Oseretsky Test of Motor Proficiency, and the self-care domain of the Pediatric Evaluation of Disability Inventory.
Results:
The reduction of spasticity in the treated muscle groups differed significantly between the control period and both study periods. Improvements on the Physician's Rating Scale score during the study period also differed significantly as compared with improvements during the control period. There was a significant difference in the improvement of fine motor skills, as measured with Bruininks-Oseretsky Test of Motor Proficiency, between the control period and both study periods. Improvements in self-care capability differed significantly between the control period and 12 wk after botulinum toxin type A treatment, but not between the control period and at 6 wk after treatment. Muscle strength of grasp and pinch did not differ significantly between the control and the study period. Distribution of body parts involvement, disease severity, and function in daily living activities had no significant correlation with functional improvement after the treatment.
Conclusions:
Our findings support the premise that botulinum toxin type A injections are effective in reducing upper limb spasticity and in improving movement pattern and fine motor function of patients with spastic cerebral palsy. A reduction in caregivers' burden and improved quality of life were demonstrated through the study period.